stockrow
Friday 6 November 2026
Export PRCT’s income statement to Excel — free account
PROCEPT BioRobotics Corporation
PRCT Healthcare Medical Devices
PROCEPT BioRobotics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $308.1 million, up 37.2% from fiscal 2024.
- Revenue
- +18.0%
- EPS
- −21.1%
- Free cash flow
- −1.57%
- Total debt
- +0.39%
Quarter to September 2026, against a year earlier
20.75
0.48
+2.37%
Follow PRCT
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.96 | 3.82 | 4.39 | 5.67 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(116.25) | (66.94) | (37.07) | (169.21) | |
P/B ratio |
3.18 | 3.79 | 4.07 | 4.78 | |
Price to Tangible BV |
3.18 | 3.80 | 4.07 | 4.79 | |
EV/Sales |
2.50 | 3.30 | 3.79 | 4.92 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(11.47) | (14.99) | (17.42) | (30.92) | |
EV/FCF |
(10.34) | (13.12) | (15.16) | (25.96) | |
Quick Ratio |
4.60 | 5.23 | 5.37 | 5.62 | |
Current Ratio |
5.89 | 6.55 | 6.73 | 6.85 | |
Net Debt/EBITDA |
6.71 | 6.94 | 6.28 | 8.01 | |
Debt/Assets |
10.93% | 10.79% | 10.61% | 10.16% | |
Debt/Equity |
0.16 | 0.15 | 0.15 | 0.14 | |
Asset Turnover |
0.72 | 0.68 | 0.64 | 0.59 | |
Operating CF/Net income |
0.34 | 0.72 | 1.21 | 0.35 | |
Capex/Depreciation |
(0.26) | (1.48) | (1.68) | (1.08) | |
Interest Coverage |
(31.98) | (32.53) | (39.86) | (34.68) | |
Research and Development Expense of Revenue |
20.36% | 21.27% | 25.82% | 24.95% | |
Selling, General and Administrative Expense of Revenue |
73.77% | 73.72% | 78.29% | 76.32% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
15.34% | 15.38% | 15.72% | 14.19% | |
Graham Net Nets |
0.26 | 0.22 | 0.20 | 0.18 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(11.09%) | (8.59%) | (7.28%) | (5.44%) | |
Free Cash Flow Yield |
(8.15%) | (6.59%) | (5.70%) | (3.34%) | |
Revenue per Share |
1.71 | 1.66 | 1.47 | 1.38 | |
Operating CF per Share |
(0.16) | (0.34) | (0.67) | (0.19) | |
Capex per Share |
(0.01) | (0.05) | (0.05) | (0.03) | |
Free Cash Flow per Share |
(0.17) | (0.39) | (0.73) | (0.22) | |
Cash per Share |
3.81 | 3.99 | 4.35 | 5.16 | |
Shareholders Equity per Share |
5.74 | 5.96 | 6.15 | 6.59 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.74 | 5.96 | 6.15 | 6.59 | |
Free Cash Flow |
(9.65) | (22.20) | (41.04) | (12.18) | |
Working Capital |
343.84 | 356.09 | 364.40 | 384.58 | |
Capital Expenditures |
(0.67) | (2.95) | (2.91) | (1.85) | |
Net Current Asset Value |
269.34 | 281.00 | 288.64 | 308.17 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.03 | 0.04 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
94.77 | 94.21 | 87.83 | 83.51 | |
Average Payables |
13.92 | 13.43 | 16.84 | 13.66 | |
Average Inventory |
74.06 | 72.05 | 69.93 | 63.43 | |
Average Assets |
492.65 | 496.20 | 503.22 | 521.05 | |
Average Common Equity |
354.59 | 362.93 | 368.41 | 384.05 |
Columns are period end dates · fundamentals updated 4 Nov 2026